Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biotech Business
Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
April 22nd, 2009
Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced the Company's unaudited financial results for the three and twelve month periods ended December 31, 2008. Full Year 2008 Financial Highlights -- Record full year 2008 sales increasing 39% year-over-year to $46.5 million -- Sold 6.93 million doses of Healive(R) in 2008, up from 5.12 million in 2007 -- Record full year net income growing of 5% to $8.01 million -- Full year EPS is $0.19 -- Cash and cash equivalents increased 93% to $32.9 million, compared to the beginning of 2008, due to an increase in operation...
Source: Vaccine Weekly (2009-04-22)
|
